Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Capital Strength UCITS ETF 06.05.2026 FTCS. IE00BL0L0D23 325,002.00 USD 10,560,173.33 32.493  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 06.05.2026 FVD. IE00BKVKW020 250,002.00 USD 7,259,472.94 29.038  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 06.05.2026 FCSG IE00BKPSPT20 1,025,002.00 USD 43,975,309.96 42.903  ...
-

UFC and Joe Hand Promotions Team Up to Offer Package of Live Combat Sports Events to Bars and Restaurants

LAS VEGAS--(BUSINESS WIRE)--UFC®, the world’s premier mixed martial arts organization, and Joe Hand Promotions, UFC’s exclusive commercial distributor throughout the United States, today announced a new premium subscription package of live sports programming available to commercial establishments in the United States, including bars and restaurants. The offering, entitled Championship Rounds, includes UFC’s full slate of 13 marquee Numbered Events and 30 Fight Nights; all cards from Zuffa Boxin...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 06.05.2026 FXGB LN IE00BD5HBR05 37,992.00 GBP 768,662.82 27.523  ...
-

Valveworks USA, Inc. Acquires Houston Oilfield Equipment, Inc.

BOSSIER CITY, La.--(BUSINESS WIRE)--Valveworks USA is pleased to announce the acquisition of Houston Oilfield Equipment, Inc., marking a significant milestone in the continued growth of Valveworks USA’s Choke Division. As part of this transaction, the Houston Oilfield legacy product lines will be integrated with Lancaster Chokes under the Valveworks USA Choke Division, ensuring continuity of product design, manufacturing expertise, and customer support. Together, these combined organizations wi...
-

JBT Marel Makes Landmark Foodservice Debut at the 2026 National Restaurant Association Show

CHICAGO--(BUSINESS WIRE)--JBT Marel, the global technology leader responsible for processing over 75% of the world’s citrus juice, is making its debut at the 2026 National Restaurant Association (NRA) Show from May 16-19. The centerpiece of this landmark debut is the Fresh’n Squeeze® 1800 Citrus Juicer, a recipient of the prestigious 2026 Kitchen Innovation Awards, showcasing how industrial-grade extraction technology has been reengineered for modern foodservice operators. The company’s strateg...
-

Andersen Consulting Strengthens Organizational Transformation Capabilities with Afiniti

SAN FRANCISCO--(BUSINESS WIRE)--Andersen Consulting announces a Collaboration Agreement with Afiniti, a global business transformation consultancy....
-

Udemy Expands AI Role Play Capabilities to Advance Immersive, Skills-Based Learning

SAN FRANCISCO--(BUSINESS WIRE)--Udemy (Nasdaq: UDMY), a leading AI-powered skills acceleration platform, today announced expanded capabilities for Role Play, its AI-powered learning experience designed to help learners build real-world professional skills through immersive practice scenarios. The new enhancements include: Greater customization, enabling organizations to tailor Role Play scenarios to specific roles, industries, and skill levels. Immersive video, introducing lifelike AI avatars t...
-

武田薬品、原発性免疫不全症(PID)を対象としたTAK-881の主要第2/3相臨床試験で良好なトップライン結果を発表

大阪およびマサチューセッツ州ケンブリッジ--(BUSINESS WIRE)--(ビジネスワイヤ) -- 武田薬品( TSE:4502/NYSE:TAK )は、原発性免疫不全症(PID)患者を対象とした主要第2/3相臨床試験であるTAK-881-3001が主要評価項目を達成し、治験薬TAK-881[皮下注用人免疫グロブリン20%溶液(SCIG 20%)および遺伝子組換えヒトヒアルロニダーゼ]とHYQVIA[遺伝子組換えヒトヒアルロニダーゼ含有皮下注用人免疫グロブリン製剤10%]との薬物動態(PK)の同等性が示されたと発表しました。さらに、副次評価項目では、ヒアルロニダーゼ促進型SCIG 20%であるTAK-881が、確立されたヒアルロニダーゼ促進型SCIG 10%であるHYQVIAと同等の安全性、有効性、忍容性プロファイルを示しました。これらの結果は、TAK-881がPID患者に必要な免疫グロブリン(IG)用量をHYQVIAの半分の注入量で投与でき、PIDでは最長で月1回(3または4週ごと)の柔軟な投与スケジュールを維持しながら、注入時間を短縮できる可能性を裏付けるものです。 TAK-...